Last reviewed · How we verify
NCT07233486: DISMA
A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD
NA trial testing Digital Intelligence Software Intervention Group in MAFLD in 2,000 participants. Currently enrolling.
30 July 2027
Quick facts
| Lead sponsor | The Affiliated Hospital of Hangzhou Normal University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 2,000 |
| Start date | 1 August 2024 |
| Primary completion | 30 July 2027 |
| Estimated completion | 30 August 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Digital Intelligence Software Intervention Group
Conditions studied
- MAFLD — all drugs for MAFLD →
Sponsor
The Affiliated Hospital of Hangzhou Normal University
Who can join
Adults 18 to 65, any sex, with MAFLD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cirrhosis associated with metabolic associated fatty liver disease (MAFLD) can lead to a series of adverse outcomes in and outside the liver, but there is no approved treatment so far. In recent years, the prevalence of MAFLD-related cirrhosis in our country is increasing rapidly, but its clinical, pathological characteristics and natural prognosis are not clear, and there is a lack of standardized and effective prevention and treatment strategies.Through"Digital Intelligence software" to assist clinicians in MAFLD patients with remote data intervention, lifestyle intervention guidance and follow-up management, to evaluate the efficacy and safety of the intervention software on body weight and blood glucose in patients with MAFLD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07233486
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for MAFLD
Currently open trials in the same condition.
- NCT06940375 — Incidence of Liver Disease-Related Outcomes in People With HIV · recruiting
- NCT06983171 — Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practi · active not recruiting
Other The Affiliated Hospital of Hangzhou Normal University trials
Trials by the same sponsor.
- NCT07241195 — A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From · not yet recruiting
- NCT07399600 — Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease · NA · not yet recruiting
- NCT06201572 — The Value of TOI in Evaluating Renal Function Damage in Hypertensive Emergency Patients · unknown
- NCT06135584 — Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07233486 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Hangzhou Normal University
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07233486.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing